Standard PAH therapy improves long term survival in CTEPH patients

Clinical Research in Cardiology

Volumn 99, Issue 9, 2010, Pages 553-556

  Seyfarth, Hans Juergen ^a   Halank, Michael ^b   Wilkens, Heinrike ^c   Schäfers, Hans Joachim ^c   Ewert, Ralf ^d   Riedel, Martin ^e   Schuster, Ernst ^a   Pankau, Hans ^a   Hammerschmidt, Stefan ^a   Wirtz, Hubert ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Pulmonary embolism; Pulmonary hypertension; Survival; Vasodilator agents

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; DIURETIC AGENT; ILOPROST; PROSTANOID; SILDENAFIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PULMONARY HYPERTENSION; SURVIVAL;

ADOLESCENT; ADULT; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77957983646     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0156-4     Document Type: Article

References (26)

1. Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schonauer V, Exner M, Klepetko W, Kneussl MP, Maurer G, Lang I (2005) Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93:512-516 (Pubitemid 40392541)
2. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, Lang IM (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128:2599-2603 (Pubitemid 41507615)
3. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ (2004) Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 23:595-600
4. Bresser P, Pepke-Zaba J, Jais X, Humbert M, Hoeper MM (2006) Medical therapies for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3:594-600
5. Dartevelle P, Fadel E, Mussot S, Chapelier A, Hervé P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, Sitbon O, Simonneau G (2004) Chronic thromboembolic pulmonary hypertension. Eur Respir J 23:637-648
6. Doyle RL, McC Douglas, Channick RN, Simmonneau G, Conte J (2004) Surgical treatments/interventions for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 126:63S-71S
7. Egermayer P, Peacock AJ (2000) Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 15:440-448
8. Ewert R, Opitz CF, Wensel R, Winkler J, Halank M, Felix SB (2007) Continous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 96:207-211
9. Fedullo PF, Auger WR, Kerr KM, Rubin LJ (2001) Chronic thromboembolic pulmonary hypertension. N Engl J Med 345:1465-1472
10. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F (2003) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167:1139-1141 (Pubitemid 36459662)
11. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schaefers HJ, Welte T, Mayer E (2005) Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128:2363-2367 (Pubitemid 41507580)
12. Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, Simonneau G, Pepke-Zaba J (2006) The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 28:138-143 (Pubitemid 44914271)
13. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ, for the BENEFiT Study Group (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. JACC 52:2127-2134
14. Mc Laughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, Rainisio M, Simonneau G, Rubin LJ (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244-249
15. Moser KM, Bloor CM (1993) Pulmonary vascular lesions occuring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103:685-692
16. Nagaya N, Shimizu Y, Satoh T, Oya H, Uematsu M, Kyotani S, Sakamaki F, Sato N, Nakanishi N, Miyatake K (2002) Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 87:340-345
17. Olschewski H, Hoeper MM, Borst MM, Ewert R, Grünig E, Kleber FX, Kopp B, Opitz C, Reichenberger F, Schmeisser A, Schranz D, Schulze-Neick I, Wilkens H, Winkler J, Worth H (2007) Diagnosis and therapy of chronic pulmonary hypertension. Clin Res Cardiol 96:301-330 (Pubitemid 46740082)
18. Olschewski H, Simonneau G, Galie N, Higgenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322-329 (Pubitemid 34815354)
19. Ono F, Nagaya N, Okumura H, Shimizu Y, Kyotani S, Nakanishi N, Miyatake K (2003) Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 123:1583-1588
20. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257-2264
21. Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism. Chest 81:151-158
22. Rosenkranz S (2007) Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 96:527-541
23. Seyfarth HJ, Hammerschmidt S, Gessner C, Halank M, Wirtz H (2006) Chronic thromboembolic pulmonary hypertension-therapeutic options. Curr Respir Med Rev 2:431-438
24. Seyfarth HJ, Hammerschmidt S, Pankau H, Winkler J, Wirtz H (2006) Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 569:1-6
25. Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J (2005) Bosentan improves exercise tolerance and Tei index in pulmonary hypertension patients with prostanoid therapy. Chest 128:709-713
26. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galie N, Humbert M, Rainisio M, Rubin LJ, Simonneau G (2005) Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60:1025-1030